Background: Selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are reported to have potent\nantiemetic effects for postoperative nausea and vomiting (PONV). The purpose of this study was to prospectively\nevaluate the efficacy of palonosetron, granisetron, and ramosetron for the prevention of PONV in patients\nundergoing laparoscopic gynecologic surgery.\nMethods: In this prospective, randomized observational study, 105 healthy female patients who were undergoing\nlaparocopic hystectomy under general anaesthesia were enrolled (clinical trial number: NCT01752374,\nwww.clinicaltrials.gov). Patients were divided into three groups: the palonostron (0.075 mg i.v.; n = 35), the\ngranisetron group (3 mg i.v.; n = 35), and the ramosetron group (0.3 mg i.v.; n = 35). The treatments were given\nbefore the end of surgery. The incidence of PONV, severity of nausea/vomiting, and the use of rescue antiemetic\nrequirements during the first 48 h after surgery were evaluated.\nResults: The overall incidence of PONV was 33.3 % for this series. The number of complete responders at 48 h after\nthe surgery was 21 (60.0 %) for palonosetron, 24 (68.6 %) for granisetron, and 26 (71.4 %) for ramosetron,\nrepresenting no statistical difference (P = 0.086).\nConclusions: There were no significant differences in the overall incidence of postoperative nausea and vomiting\nand complete responders for palonosetron, granisetron and ramosetron group.
Loading....